Abstract
Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells with the PSC-derived hematopoietic progenitors (HPs), leading to efficient differentiation to T lymphocytes. In addition, we describe a protocol for robust T cell generation from hPSCs conditionally expressing ETS1. The presented protocols provide a platform for T cell production for disease modeling and evaluating their use for immunotherapy in large animal models.
Original language | English (US) |
---|---|
Pages (from-to) | e3675 |
Journal | Bio-protocol |
Volume | 10 |
Issue number | 13 |
DOIs | |
State | Published - Jul 5 2020 |
Externally published | Yes |
Bibliographical note
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.PubMed: MeSH publication types
- Journal Article